Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:G01N33/48

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20220308057METHOD FOR DETERMINING ONSET RISK OF CARDIOVASCULAR DISEASE IN SUBJECT, AND METHOD FOR DETERMINING VASCULAR CALCIFICATION IN SUBJECT
US 29.09.2022
Int.Class G01N 33/573
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
573for enzymes or isoenzymes
Appl.No 17675194 Applicant SYSMEX CORPORATION Inventor Maria KIRIYAMA

Disclosed is a method of determining onset risk of cardiovascular disease in a subject, the method comprising:

    • capturing, on a solid phase, an extracellular vesicle derived from a blood sample collected from the subject; and
    • measuring alkaline phosphatase activity of the extracellular vesicle,
    • a measured result of the alkaline phosphatase activity being directed for use as an index of the onset risk of cardiovascular disease in the subject.

2.20220308056BIOMARKER FOR ASSESSING THE RISK OF DEVELOPING ACUTE COVID-19 AND POST-ACUTE COVID-19
US 29.09.2022
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
Appl.No 17665176 Applicant Omeros Corporation Inventor Gregory A. Demopulos

Disclosed herein are compositions, kits and methods for determining the concentration of fluid-phase MASP-2/C1-INH complex in a biological fluid, such as a biological fluid obtained from a subject infected with SARS-CoV-2. Also disclosed are methods of using said compositions, methods and kits for detection of MASP-2/C1-INH complex to determine the status of lectin pathway activation in a mammalian subject and thereby assess the risk of a subject that is or has been infected with SARS-CoV-2 for developing COVID-19-related ARDS or other poor outcome, or determine the need for treatment or efficacy of treatment of a subject in need thereof with a complement inhibitor such as a MASP-2 inhibitory agent.

3.WO/2022/200438DIGITAL SENSOR WITH REFERENCE CANTILEVER FOR CONVERTING CHEMICAL AND/OR BIOCHEMICAL INFORMATION
WO 29.09.2022
Int.Class G01N 33/543
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
543with an insoluble carrier for immobilising immunochemicals
Appl.No PCT/EP2022/057647 Applicant DIGID GMBH Inventor KLOPPSTECH, Konstantin
The invention relates to a sensor (1) for converting chemical and/or biochemical information of an analyte (90) in a sample (9) into an electric signal, comprising a test cantilever (2) which has a base (20) and a deformable part (22). A receptor layer (24) is applied at least onto the deformable part in order to selectively receive an analyte (90) of the sample (9), a passive test transducer (200) is arranged on the base (20), and an active test transducer (1020) is arranged on the deformable part (220). The sensor also comprises a reference cantilever (3) which has a base (30) and a deformable part (32). A reference layer (34) is applied onto the deformable part (32) in order to selectively not receive the analyte (90), a passive reference transducer (300) is arranged on the base (30), and an active reference transducer (320) is arranged on the deformable part (32), wherein the active and passive reference transducers (320, 300) and the active and passive test transducers (220, 200) are designed to output an electric signal corresponding to the presence and/or concentration of the analyte (90) in the sample (9).
4.WO/2022/200303METHODS FOR THE DIAGNOSIS AND TREATMENT OF T CELL-LYMPHOMAS
WO 29.09.2022
Int.Class A61P 35/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
04specific for metastasis
Appl.No PCT/EP2022/057408 Applicant INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) Inventor BENSUSSAN, Armand
T-cell lymphomas are a heterogeneous group of malignancies involving T lymphocytes and generally characterized by a poor prognosis. Among them, cutaneous T-cell lymphomas involve primarily the skin. Mycosis fungoides and Sezary syndrome are the most frequent cutaneous T-cell lymphomas. The inventors studied the regulatory T phenotype of Sezary cells and showed the expression of CCR8 (CD198) by Sezary cells and other T-cell lymphoma cell lines. CCR8 therefore appears as a useful diagnostic, prognostic and follow-up marker, and as a potential therapeutic target in T-cell lymphomas. Therapeutic depletion of CCR8-expressing cancer cells would eliminate tumor cells and also activate the anti-tumor immunity in T-cell lymphomas.
5.WO/2022/200573METHOD OF DETERMINING PROGNOSIS OF CHRONIC KIDNEY DISEASE
WO 29.09.2022
Int.Class G01N 33/68
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
Appl.No PCT/EP2022/057927 Applicant RANDOX LABORATORIES Inventor MCCONNELL, Ivan
The current invention provides methods which can be implemented alongside clinical variables as risk prediction tools for improved prediction of CKD progression and mortality. Surprisingly it was found that decreased C3a-desArg was associated with adverse outcome in CKD, and when combined with increased STNFR1 and NGAL it gave an excellent predictor of progression to a composite endpoint in CKD patients.
6.WO/2022/203018IMMUNOCHROMATOGRAPHIC TESTING DEVICE
WO 29.09.2022
Int.Class G01N 35/00
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
35Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/-G01N33/148; Handling materials therefor
Appl.No PCT/JP2022/014115 Applicant FUJIFILM CORPORATION Inventor TANAKA, Yasutake
According to the present invention, a testing device comprises: a loading unit into which a cartridge can be removably loaded, the cartridge comprising a support that has a test area and a spotting area onto which a sample is to be spotted; an imaging unit that captures an image of the test area; and a processor that performs a principal determination on the basis of the test area image captured by the imaging unit, the principal determination being a determination of whether the sample is positive or negative. The test area image is a two-dimensional matrix of pixels, and the processor performs abnormality determination that determines whether there is an abnormality in the test area image using, as a determination index, at least one of the difference between a relatively large pixel value and a relatively small pixel value for at least one column of the test area image and a standard deviation and a coefficient of variation that are based on the pixel values for each column. The processor determines processing details for the principal determination on the basis of whether there is an abnormality.
7.WO/2022/202853EFFICACIOUS ANTI-CD26 ANTIBODY BIOMARKER
WO 29.09.2022
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/JP2022/013309 Applicant Y'S AC CO., LTD. Inventor MORIMOTO, Chikao
In the present invention, a potential prognostic biomarker for CD26-targeted therapy was identified based on phase I trial data of the humanized anti-CD26 monoclonal antibody YS110 for CD26-expressing tumors. Box-and-whisper plot analysis, scatter plot analysis, Pearson's product-moment correlation/Spearman's rank-order correlation, bar graph analysis and receiver operating characteristics (ROC) were used to examine the correlation between soluble CD26 titer variation with YS110 administration and tumor volume change, RECIST criteria evaluation and progression free survival (PFS). The mechanism for serum soluble CD26 titer variation was confirmed by in vitro experimentation. As a result, it was discovered, for the first time, that serum soluble CR26/DPP4 titer variation in the early stage of YS110 treatment is a predictive biomarker for evaluating thereapeutic effect.
8.WO/2022/203603WATER-SOLUBLE POLYMER TO PREVENT NON-SPECIFIC ADSORPTION
WO 29.09.2022
Int.Class C08L 43/02
CCHEMISTRY; METALLURGY
08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
43Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing boron, silicon, phosphorus, selenium, tellurium, or a metal; Compositions of derivatives of such polymers
02Homopolymers or copolymers of monomers containing phosphorus
Appl.No PCT/SG2022/050158 Applicant N-LAB TECHNOLOGY CENTER PTE. LTD. Inventor WANG, Honglei
The present invention relates to a water-soluble copolymer which prevents nonspecific adsorption of bio-substances, such as proteins and the like. It mainly applies to reagent, particles and the like which are used in clinical diagnoses, biochemical experiments, medical devices and the like.
9.20220304618IMPEDANCE-TYPE CHIP FOR REAL-TIME SENSING SWEAT PRESSURE AND METHOD THEREOF
US 29.09.2022
Int.Class A61B 5/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
BDIAGNOSIS; SURGERY; IDENTIFICATION
5Measuring for diagnostic purposes; Identification of persons
Appl.No 17212098 Applicant National Yang Ming Chiao Tung University Inventor Bor-Ran Li

An impedance-type chip for real-time sensing sweat pressure, a micro-control system, and method thereof are provided for monitoring a physiological state of a subject. The impedance-type chip includes a substrate, a pair of comb-shaped electrodes, a first double-layered junction plate, a microfluidic channel plate, a second double-layered junction plate, and a sealing plate. Each the comb-shaped electrodes has a plurality of sub-electrodes and is disposed on the substrate to provide different impedance values. The first double-layered junction plate is disposed on the substrate, the microfluidic channel plate is disposed on the first double-layered junction plates, and the second double-layered junction plate is disposed on the microfluidic channel plate, wherein the first double-layered junction plate, the microfluidic channel plate, and the second double-layered junction plate have a microfluidic channel with a cavity. The sealing plate is disposed on the second double-layered junction plate to seal the microfluidic channel.

10.WO/2022/201774INTERFACE DETECTION SENSOR AND INTERFACE DETECTION METHOD
WO 29.09.2022
Int.Class G01N 33/48
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
Appl.No PCT/JP2022/001238 Applicant PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD. Inventor NAGASAKA Kenshiro
An interface detection sensor (100) comprises: a light projecting unit that successively projects, onto a detection target having a plurality of layers, projected light sets including first projected light having a first wavelength and second projected light having a second wavelength; a light receiving unit that successively receives received light sets including first received light produced when the first projected light passes through the detection target, and second received light produced when the second projected light passes through the detection target; and a control unit that detects the interfaces of the plurality of layers included in the detection target, on the basis of the received light sets that have been received successively. The light projecting unit begins projecting the second projected light either while the first projected light is being projected or after the same has finished being projected.